Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Editas Medicine, Inc.

< Previous 1 2 Next >
Editas Medicine Announces Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Pricing of Offering of Common Stock
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Offering of Common Stock
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Reports Inducement Grant to New Chief Financial Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces First Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Third Quarter 2022 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.